NinePoint Medical, a 2012 Fierce 15 winner, has launched its NvisionVLE imaging system in the U.S., all part of the company's plan to get profitable and expand its technology.
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.
After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
Taris Biomedical has gone back to the venture well as the biotech startup launches a midstage study of its lead candidate against bladder pain. The Lexington, MA-based company found support for its latest financing from previous backers at Flybridge Capital Partners, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.
Venture capitalists have been focusing more on companies that are close to commercialization. But even as the venture capital industry has shifted its priorities to safer bets, VCs like Bob Tepper continue to keep early-stage investment prospects very much in mind.
An Ohio medical device company pulled in a $9 million Series B round to support the commercial rollout of a high-tech laparoscopic device attachment designed to keep the camera clean during a procedure.
Third Rock Ventures is jumping into the early-stage venture investment void with a new $516 million fund that will launch up to 16 new medical device, diagnostic and drug companies that bring something new and disruptive to the marketplace.
Third Rock Ventures has established its third biotech fund in 6 years, bringing in a haul of $516 million for one of the most active groups of early-stage biotech investors in the world. The new fund, which brings the total it's raised to a whopping $1.3 billion-plus, will be used to launch another 16 or so drug developers.
DC devices is developing the first technology that can treat diastolic heart failure without the need for invasive surgery, and the startup has snagged $10.7 million in venture financing.
Third Rock Ventures has made quite a few big biotech gambles in recent years. And now we know just how well one of them paid off. In a 10-K filed with the SEC, Shire detailed--for the first time-- its $49.3 million upfront payment to acquire Lotus Tissue Repair, which the venture group had a controlling interest in. And Shire added $275 million in milestones, to further sweeten the package. Read more >>